- Home
- DRRX vs IBIO Comparison
DRRX vs IBIO Comparison
Compare DRRX & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- IBIO
- Stock Information
- Founded
- DRRX 1998
- IBIO 2008
- Country
- DRRX United States
- IBIO United States
- Employees
- DRRX N/A
- IBIO N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- IBIO Health Care
- Exchange
- DRRX Nasdaq
- IBIO Nasdaq
- Market Cap
- DRRX 26.3M
- IBIO 24.3M
- IPO Year
- DRRX 2000
- IBIO N/A
- Fundamental
- Price
- DRRX $0.80
- IBIO $3.48
- Analyst Decision
- DRRX Buy
- IBIO Strong Buy
- Analyst Count
- DRRX 2
- IBIO 3
- Target Price
- DRRX $5.00
- IBIO $4.87
- AVG Volume (30 Days)
- DRRX 54.3K
- IBIO 299.1K
- Earning Date
- DRRX 03-26-2025
- IBIO 02-10-2025
- Dividend Yield
- DRRX N/A
- IBIO N/A
- EPS Growth
- DRRX N/A
- IBIO N/A
- EPS
- DRRX N/A
- IBIO N/A
- Revenue
- DRRX $8,594,000.00
- IBIO $375,000.00
- Revenue This Year
- DRRX $54.32
- IBIO $36.00
- Revenue Next Year
- DRRX N/A
- IBIO $33.33
- P/E Ratio
- DRRX N/A
- IBIO N/A
- Revenue Growth
- DRRX N/A
- IBIO 650.00
- 52 Week Low
- DRRX $0.70
- IBIO $1.05
- 52 Week High
- DRRX $1.88
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- DRRX 49.63
- IBIO 55.25
- Support Level
- DRRX $0.73
- IBIO $3.22
- Resistance Level
- DRRX $0.83
- IBIO $3.76
- Average True Range (ATR)
- DRRX 0.05
- IBIO 0.38
- MACD
- DRRX 0.01
- IBIO 0.00
- Stochastic Oscillator
- DRRX 63.57
- IBIO 56.41
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.